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Chronic Idiopathic Intestinal Pseudo-Obstruction: 
A Working Diagnosis
Ankush Kalra, MD and Anthony J DiMarino, MD
InTroduCTIon
Chronic intestinal pseudo-obstruction (CIP) is a 
rare and disabling motility syndrome, yet one that 
demands an extensive review of digestive motility and 
peristaltic pathophysiology. Primarily a disorder of the 
small intestine, CIP was first described by Dudley and 
colleagues in 1958; it is defined by severe signs and 
symptoms of intestinal obstruction (abdominal pain 
and distention, nausea, vomiting, and constipation), in 
addition to radiographic evidence of dilated bowel in the 
absence of a true, mechanical obstruction. Symptoms 
are often slowly progressive and diagnosis requires the 
presence of symptoms for at least six months.1 A 2013 
national survey in Japan estimated the prevalence of 
CIP at 0.8 to 1.0 per 100,000, with an incidence rate 
of 0.21 to 0.24 per 100,000. In the same survey, the 
mean age at diagnosis is 63.1 years for males and 59.2 
for females.2 CIP encompasses an extensive differential 
diagnosis, a complex, multidisciplinary work-up, and 
a vast array of potential treatment options based in 
intricate pathophysiology.
CaSE PrESEnTaTIon:
RC is a 75-year-old male who presented with recurrent 
small bowel obstructions (SBOs) between August and 
September 2014. He has no chronic medical conditions, 
and his past medical history is significant only for a 
community-acquired pneumonia and pleural empyema 
at age 50. His surgical history is significant only for a right 
inguinal hernia repair at age 7. Initially, his symptoms 
began in April 2014 and were mild, limited to constipation 
relieved with over the counter laxatives. After two brief 
admissions for SBOs that resolved with nasogastric tube 
decompression, RC presented on September 9, 2014 
with a distended, tympanitic abdomen with absence 
of bowel sounds and minimal tenderness to palpation. 
A computed tomography (CT)  scan demonstrated 
multiple dilated loops of small bowel with a transition 
point in the proximal ileum. A nasogastric tube was 
again placed but the obstruction persisted clinically and 
on repeat X-Rays. During an exploratory laparoscopy 
on September 15, 2014, the right colon and entire small 
bowel were palpated. No transition zone or small bowel 
abnormality was found and the peritoneal surfaces of 
all abdominal organs appeared normal. Ultimately, an 
ileocecectomy was performed and RC underwent a 
thorough diagnostic workup.
dIFFErEnTIal dIagnoSIS:
While CIP is a rare and elusive diagnosis, it is not one of 
exclusion. It is a clinical diagnosis typically confirmed 
by endoscopic or radiologic exclusion of a mechanical 
obstruction. In the case of RC, the lack of mechanical 
obstruction was confirmed by manual palpation of the 
entire small bowel and colon. The rest of the workup 
focused on the etiology of CIP, which may be either 
idiopathic or secondary. Secondary CIP was ruled out 
with lab testing for collagen vascular diseases, hypothy-
roidism, diabetes, porphyria, and celiac disease, as well 
as a lack of any iatrogenic factors. A thorough paraneo-
plastic work-up was unremarkable; Ho, Yu, and neuronal 
nuclear antibodies were negative, CT scan of the thorax 
ruled out thymoma, thyroid ultrasound revealed benign 
nodules, and testicular ultrasound demonstrated no 
masses. The ileocecectomy specimen demonstrated 
small bowel mucosa with prominent reactive lymphoid 
hyperplasia. While nonspecific, this pathology is most 
consistent with an inflammatory neuropathy.
ouTCoME/Follow-uP:
An exploratory laparotomy performed on September 
24, 2014 demonstrated significantly dilated small bowel 
at the ligament of Treitz. There was no evidence of 
mechanical obstruction such as mass, adhesions, 
stricture, kinking, or intussusception. Palpation of 
the colon was normal minus significant transverse 
colon dilation. Ileocecectomy was performed and a 
gastrostomy tube was also placed for venting. With 
continued symptoms and radiographic pseudo-
obstruction after ileocecectomy, RC was started on total 
parenteral nutrition (TPN). After failure of stool softeners, 
laxatives, and prokinetic lubiprostone, treatment with 
prokinetic linaclotide was initiated. Moderate success 
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was achieved with the addition of somatostatin analog 
octreotide and antibiotic rifaximin, as RC began to move 
his bowels. Acetylcholinesterase inhibitor neostigmine 
was also administered with successful movement of the 
bowels within less than five minutes, further supporting 
a neuropathic etiology. Ultimately, RC was discharged 
on October 14, 2014 with linaclotide, octreotide, 
polyethylene glycol, and TPN. Significant progress was 
made over the ensuing months, as he began to tolerate 
oral intake, discontinued TPN, and had his medications 
tapered. Currently, RC only takes linaclotide twice 
weekly and maintains a gastrostomy tube for intermittent 
venting. He has returned to his normal lifestyle and has 
daily, formed bowel movements without symptomatic 
or radiographic evidence of bowel obstruction. 
dISCuSSIon:
Reflecting on the case of RC, it can be said that the true 
mechanism of his return to health remains uncertain. 
CIP is classified using three histological categories: 
neuropathies (either inflammatory or degenerative), 
myopathies (smooth muscle fibrosis), and mesenchy-
mopathies (dysfunction of the pacemaker interstitial 
cells of Cajal). Inflammatory neuropathies are the most 
common cause of CIP, defined by myenteric plexus 
ganglionitis and encompassing etiologies such as 
paraneoplastic syndromes, infections, and connective 
tissue disorders.1 Interestingly, most case reports 
describe CIP as the first presentation of another disease, 
most commonly small cell lung cancers, lupus, and 
scleroderma.3 While the appropriate screening tests 
were done for these conditions, one 2012 case report 
describes CIP as the initial manifestation of an atypical, 
seronegative systemic sclerosis.4 Octreotide has been 
used with much success in CIP secondary to scleroderma. 
Gastrointestinal transit studies have demonstrated that, 
while octreotide has been proven to slow intestinal transit 
by inhibiting intermittent, low-amplitude contractions, it 
enhances short burst, high amplitude contractions.5 A 
1991 study demonstrated that scleroderma patients with 
an inability to generate migrating motor complexes were 
able to produce 3.6 complexes every three hours after 
administration of 100 micrograms of octreotide.6 The 
stasis associated with CIP is believed to generate a cycle 
of small intestinal bacterial overgrowth (SIBO) that leads 
to mucosal inflammation and further dysmotility1, and 
this might explain why RC developed transverse colon 
dilation later on in his course. While rifaximin and other 
antibiotic regimens are often used to treat SIBO, it has 
been demonstrated that 50 micrograms of octreotide 
every evening for three weeks will reduce breath 
hydrogen excretion, a marker of SIBO, from 25 to 4 parts 
per million.6 Therefore, the SIBO that is both a contributor 
to and consequence of CIP may be successfully treated 
by targeting small intestinal motility. As CIP generally has 
a chronic, relapsing course and overall poor prognosis, 
it is important to regularly monitor these patients and 
remain vigilant about pursuing further workup and 
therapies with any change in clinical status.   
KEy PoInTS:
The case of RC is a complicated one defined by 
uncertainty and a multitude of diagnostic and therapeutic 
interventions. While he is currently symptom free and 
maintained only on linaclotide twice weekly, history 
tells us that this case may soon be revisited and a more 
certain diagnosis obtained. While there is a need for 
physicians to become knowledgeable about CIP, the 
medical community must continue to inquire about 
targeted therapies. It is essential that these stories be 
shared. The pathophysiological basis of treatments used 
in these cases continues to be a key focus of research.
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